Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad.asHsp70 is a recombinant adenoviral vector expressing antisense heat shock protein 70 (Hsp70) cDNA. Developed by researchers at the Danish Cancer Society, it is designed to selectively deplete Hsp70 in tumor cells. Hsp70 is an antiapoptotic chaperone protein that is highly expressed in human tumors and protects them from lysosomal membrane permeabilization and cell death. Depletion of Hsp70 by Ad.asHsp70 triggers lysosomal membrane permeabilization, leading to the release of lysosomal cysteine proteases (cathepsins) into the cytosol and inducing massive, caspase-independent, tumor-specific cell death. In preclinical models, locoregional administration of Ad.asHsp70 has demonstrated efficacy in eradicating xenografts of glioblastoma, breast carcinoma, and colon carcinoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ad.asHsp70.